Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Dr Ayaz Ahmed, ICCBS – University of Karachi, Pakistan

Dr. Ayaz Ahmed 🧬🔬 is a Principal Investigator and Assistant Professor at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), ICCBS, University of Karachi, Pakistan. With a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China, and an M.Sc. in Microbiology from the University of Karachi, his research focuses on microbial profiling, anti-biofilm agents, and infectious disease models. Dr. Ahmed has supervised numerous postgraduate students and received multiple international awards, including recognition from the American Society for Microbiology and Bill & Melinda Gates Foundation. He also leads funded projects on combating antibiotic-resistant pathogens. 🌟

Publication Profile

google scholar

Qualifications

Dr. Ayaz Ahmed holds a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China (2012), and a Master’s in Microbiology from the University of Karachi, Pakistan (2006, First Division). 🧬🎓 His doctoral research focused on the “Microbial profiling of dental plaque/Biofilm from dental caries and periodontitis patients” and explored the effects of Lactobacillus species on S. mutans biofilm formation. 🦷🔬 With a strong academic foundation and research expertise in microbiology and molecular biology, Dr. Ayaz contributes significantly to the understanding of microbial interactions in dental health and disease. 🌟

Job Responsibilities

Dr. Ayaz Ahmed is a Principal Investigator at the Cell Biology Lab, where he oversees the Imaging Facility, maintaining high-end fluorescence and light microscopes. He supports students by assisting them in acquiring high-quality images for their theses and manuscripts. Dr. Ahmed also manages the National Animal Facility for Laboratory Animal Research and Care. He supervises routine animal house operations and collaborates with a veterinary doctor to maintain SPF rats, mice, and hamsters. He is responsible for establishing models for infectious diseases and memory deficits to evaluate the efficacy of natural compounds. Dr. Ahmed also conducts toxicological studies and trains students in ethical animal research practices. 🧬🔬🐁

Student Supervised

Dr. Ayaz Ahmed and his team of dedicated researchers have made significant strides in their exploration of innovative therapeutic strategies. Among the Ph.D. candidates, Zulfiqar Ahmed’s research on controlling salmonellosis through probiotics in poultry, Binte Zehra’s study on modulating the metastatic potential of NSCLC, and Jazib Shafiq’s investigation into gut dysbiosis and anxiety have all been awarded. Additionally, Afshan Shams, Yamina Usmani, and Shariqa Khuwaja are examining the potential of natural and synthetic compounds in combating oral cancer and other diseases. Several M. Phil. students are also contributing to research on antimicrobial resistance and cancer therapies. 🧪🔬🧫

Honors and Awards

Dr. Ayaz Ahmed has earned numerous accolades throughout his distinguished career. In 2024, he received the Award for Collaborative Scientific Achievement from the Institute of Food Science and Technology, Chinese Academy of Agriculture Science, Beijing. He also became an International Federation for Biosafety Association (IFBA) Certified Biological Waste Management Professional and Bio-risk Management Professional in 2023. Dr. Ahmed was selected as a Mentor for the ASM Future Leaders Mentoring Fellowship Program in 2023 and was awarded the Health Security Partner Grant by the Bill & Melinda Gates Foundation in 2021. He has also earned prestigious travel awards and fellowships, including the American Society for Microbiology ID Fellowship and the Science and Technology Talent Award. 🏅🌍🦠

Completed Projects

Dr. Ayaz Ahmed has led multiple impactful research projects focused on combating multidrug-resistant microorganisms and improving public health. His research on the effect of synthetic and natural compounds on biofilm formation was funded by the Higher Education Commission of Pakistan (HEC) under project # HEC No: PD-IPFP/HRD/HEC/ 2013/1182. He also contributed to projects such as Personal Protective Equipment for Sindh Poultry Vaccine Center (funded by CRDF Global, USA), and oral pathogens related to dental caries (funded by ICCBS). Notably, his work on antimicrobial-resistant water contaminants, funded by the U.S.-Pakistan Centers for Advanced Studies in Water, aims to improve water quality. He further advanced research on antimicrobial and antibiofilm agents targeting Acinetobacter baumannii and Klebsiella pneumonia with funding from HEC. 💧🔬🦠

Professional Experience

Dr. Ayaz Ahmed has had a distinguished career in academia and research. Since June 2017, he has been serving as an Assistant Professor at the International Center for Chemical and Biological Sciences, University of Karachi. Prior to this, he worked as a Senior Research Officer at the same institution from November 2013 to June 2017. Dr. Ahmed also pursued Post-Doctoral training in Behavioral Sciences at Hunan Drug Safety Evaluation in Changsha, China, from January 2016 to February 2017. His earlier roles include Assistant Professor on Interim Placement, Research Officer in Avian Influenza Vaccine Production, and a research intern in the National Internship Program. 🧪📚

Professional Membership

Dr. Ayaz Ahmed is an active member of several prestigious professional organizations, contributing significantly to the fields of microbiology and infectious diseases. His memberships include the American Society for Microbiology (ASM) 🦠, the Pakistan Biological Safety Association (PBSA) 🧫, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 🌍. Additionally, he is a member of the American Association of Cancer Research (AACR) 🎗️ and the Medical Microbiology & Infectious Disease Society of Pakistan (MMIDSP) 🇵🇰. These memberships reflect his commitment to advancing research and innovation in microbiology, infectious diseases, and cancer research.

Research Focus

Dr. Ayaz Ayaz Ahmed research focus primarily revolves around microbiology, particularly in the fields of gut microbiota analysis, antimicrobial resistance, and biofilm formation. His studies often investigate the interactions between microorganisms and the human or animal host, such as comparing gut microbe profiles between healthy individuals and those with conditions like hyperthyroidism and liver cirrhosis. Additionally, Dr. Ahmed explores innovative therapeutic approaches, including the development of antimicrobial agents, such as nanoparticles conjugated with antibiotics to combat biofilm-forming pathogens like Klebsiella pneumoniae and Staphylococcus aureus. His work has significant implications for medical microbiology and the treatment of infectious diseases. 🦠🔬

Publication Top Notes

Gut microbe analysis between hyperthyroid and healthy individuals

Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan

Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella pneumoniae

Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals

Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae

Effect of Lactobacillus species on Streptococcus mutans biofilm formation.

Comparison of oral microbiota in orthodontic patients and healthy individuals

Synthesis and Chemosensing of Nitrofurazone using Olive oil based Silver Nanoparticles (O-AgNPs)

Isolation of dihydrobenzofuran derivatives from ethnomedicinal species Polygonum barbatum as anticancer compounds

Ajaz Ahmad| Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Ajaz Ahmad | Drug Delivery Systems| Best Researcher Award

 King Saud University, Saudi Arabia

Author Profile

🎓Early Academic Pursuits 

Professor Ajaz Ahmad began his distinguished academic journey at the prestigious Hamdard University in New Delhi, India. He earned a Bachelor of Pharmacy (B.Pharm) in 2005, where he demonstrated an early inclination toward pharmaceutical sciences. Continuing his education at the same institution, he completed a Master of Pharmacy (M.Pharm) in 2007, refining his focus on drug delivery and molecular pharmacology. Driven by a passion for research, he pursued a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences, which he completed in 2011. His doctoral research laid the foundation for his expertise in drug discovery, pharmacokinetics, and the molecular mechanisms underpinning drug actions.

💼Professional Endeavors 

King Saud University, Saudi Arabia
Prof. Ahmad joined the College of Pharmacy at King Saud University in 2011 as an Assistant Professor in Clinical Pharmacy. Over the next decade, his contributions to research and teaching led to successive promotions—first as an Associate Professor in 2017 and then to his current role as Professor in Clinical Pharmacy in January 2024. At King Saud University, Prof. Ahmad’s role encompasses teaching advanced courses, mentoring postgraduate students, and conducting cutting-edge research in pharmacology and drug development.International Collaborations
Since 2015, Prof. Ahmad has served as a research collaborator with the Mayo Clinic, USA, a testament to his global reputation in pharmaceutical sciences. In 2013, he was appointed an Honorary Research Associate at the University of Hong Kong, further broadening his academic and professional network.Patents and Industry EngagementProf. Ahmad holds a U.S. patent (US20170231925A1) for treating neurovascular complications of diabetes mellitus. This innovation highlights his commitment to bridging the gap between research and practical healthcare applications.

🔬Contributions and Research Focus 

Prof. Ahmad’s research covers a broad spectrum of topics in pharmaceutical sciences, with particular focus areas including:Preclinical Drug Development: He has explored novel therapeutic agents, focusing on their efficacy, safety, and molecular mechanisms.Pharmacokinetics and Drug Metabolism: His work delves into the ADME (absorption, distribution, metabolism, and excretion) properties of drugs, optimizing formulations and dosing regimens.Bioanalytical Method Development: Prof. Ahmad designs and validates analytical methods for drug quantification, ensuring reproducibility and precision.Animal Models for Disease Research: He conducts in vivo studies simulating human diseases like cancer, diabetes, and cardiovascular disorders, with a focus on ethical handling and translational applications.Sepsis Research: Investigating biomarkers for early diagnosis and developing therapeutic strategies to combat sepsis.Vascular Pharmacology: Using myography techniques, he explores interventions for vascular diseases and evaluates novel therapeutic targets.

📖Notable Publications

Molecular insights into anti-Protozoal action of natural compounds against
  • Authors : Raish M; Ahmad A; MOHD SHAHNAWAZ KHAN; Kalam MA
  • Journal: biomolecular structure & dynamics
  • Year: 2023
A BOX-BEHNKEN DESIGN FOR OPTIMIZATION OF ULTRASOUND-ASSISTED EXTRACTION OF SINAPIC ACID FROM FRAGARIA ANANASSA
  • Authors : Mudassar Shahid; Ahmad A; Raish M; Bin Jardan YA; Alkharfy KM; Ahad A; Abul Kalam M; Ahmad Ansari M; Iqbal M; Ali N et al.
  • Journal: Pharmaceutical Society
  • Year: 2023
Sinapic acid alleviates 5-fluorouracil-induced nephrotoxicity in rats via Nrf2/HO-1 signalling.
  • Authors : Ahmad Ansari M; Shahid M; Ahmad SF; Ahmad A; Alanazi A; Malik A; Bin Jardan YA; Attia SM; Bakheet SA; Raish M
  • Journal: Pharmaceutical Sciences
  • Year: 2023
A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment
  • Authors : Zhang, M., Si, S.J., Dai, W.J., … Jin, F., Jiang, L.Q.
  • Journal: Pharmaceutical Society
  • Year: 2023
Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism.
  • Authors : Mohammad raish; Ahmad A; Mudassar Shahid; Yousef A Bin Jardan; Abdul Ahad; Dr Mohd Abul Kalam; Mushtaq Ahmad Ansari; Muzaffar Iqbal; Ali N; Alkharfy KM et al.
  • Journal:Molecules
  • Year: 2023

Assoc Prof Dr. Fatemeh Moradian| Drug Discovery and Development |Best Researcher Award

Published on by Top Pharmaceutical

Assoc Prof Dr. Fatemeh Moradian|Drug Discovery and Development|Best Researcher Award

Assoc Prof Dr. Fatemeh Moradian at Sari Agricultural Sciences and Natural Resources University,Iran

PROFILE  

orcid

 

Early Academic Pursuits 🎓

Fatemeh (Elham) Moradian began her academic journey with a B.Sc. in Biology from the University of Shiraz in 1996. Her passion for biochemistry soon led her to pursue further studies at Tarbiat Modares University, where she earned both her M.Sc. in Biochemistry in 2000 and a Ph.D. in Biochemistry in 2006. Her doctoral research, with its focus on enzymology and the intricate biochemical mechanisms involved in living organisms, set the stage for a prolific academic and research career. During this time, she developed expertise in protein structure and function, which later became a cornerstone of her research.

Professional Endeavors 💼

Following the completion of her Ph.D., Dr. Moradian joined Sari Agricultural Sciences and Natural Resources University (SANRU), where she has been a faculty member from 2006 to 2019. Throughout her tenure, she has taught several advanced courses, including Biochemistry, Enzymology, Biochemistry Mechanisms of Cancer, Animal Cell Culture, and Bioinformatics. Her teaching approach, known for integrating practical applications and research into the curriculum, has shaped many aspiring scientists and biochemists.
Dr. Moradian also had the opportunity to undertake a sabbatical at the University of Alberta in Canada, where she worked at the prestigious Michael James Lab in the Department of Biochemistry. During this 7-month research period (2005-2006), she contributed to a project focused on the structural genomics of Mycobacterium tuberculosis, honing her expertise in microbial biochemistry and structural analysis.

Contributions and Research Focus 🔬

Dr. Moradian’s research interests span a wide array of biochemistry-related fields, but her core focus lies in enzymology, protein purification, cancer research, and microbial biochemistry. Her research on the isolation, purification, and characterization of novel enzymes has made significant contributions to both environmental and medical biotechnology. One of her early landmark studies involved the isolation and characterization of an alkaline protease from Bacillus sp HS-08, which was presented at the International Conference on Environmental, Industrial, and Applied Microbiology in Spain in 2005.

Her research has taken her across the globe, presenting papers at prestigious international conferences in countries like China, France, the Netherlands, and Russia. Her work on thermostable proteases and their resistance to extreme conditions has significant implications for industrial biotechnology, especially in detergent and solvent industries.

One of her notable research projects involved studying the inhibitory effects of silver (Ag) and iron (Fe) colloidal nanoparticles on P. aeruginosa and E. coli growth, presented at the 17th International Conference on Biotechnology and Nanotechnology in Venice, Italy, in 2015. This work highlights her foray into nanotechnology and its biomedical applications, particularly in developing antimicrobial agents.

Accolades and Recognition 🏅

Throughout her career, Dr. Moradian has gained international recognition for her research contributions. She has been invited to present her work at numerous prestigious conferences, where her findings have been well-received by the global scientific community. Her work on cancer research, particularly the cytotoxic effects of caffeic acid extracted from Echinacea purpurea on human gastric cancer cells, has garnered significant attention. Presented at the International Conference on Medical and Health Sciences in Saint Petersburg, Russia, in 2018, this study underscores her commitment to discovering new avenues for cancer treatment using natural compounds.

Additionally, Dr. Moradian’s research on lactoferrin and its antimicrobial and anticancer effects, which she presented at various conferences in Paris and Indonesia, has positioned her as a key contributor to the field of medical biochemistry, particularly in exploring non-invasive treatments for stomach adenocarcinoma.

Impact and Influence 🌍

Dr. Moradian’s contributions have not only advanced scientific knowledge but have also inspired future generations of scientists. Through her teaching and mentorship, she has guided numerous students toward successful careers in biochemistry and biotechnology. Her integration of theoretical knowledge with real-world applications has been particularly influential in shaping her students’ understanding of the critical role biochemistry plays in solving global challenges, from environmental sustainability to cancer treatment.

Her research on thermostable enzymes and antimicrobial nanoparticles continues to have a broad impact on industries ranging from pharmaceuticals to environmental sciences. Additionally, her work on stress responses in plants, particularly the superoxide dismutase activity in salt stress conditions in Aeluropus littoralis, has implications for agricultural biotechnology and improving crop resilience.

Legacy and Future Contributions 🌱

As an established biochemist with a strong research portfolio, Dr. Moradian’s legacy is already well-established in the fields of enzymology, cancer research, and microbial biochemistry. However, her work is far from over. She continues to explore new frontiers in biochemistry, particularly in the areas of cancer therapeutics and environmental biotechnology. With her vast experience and network of international collaborators, Dr. Moradian is poised to make further groundbreaking contributions to science.
Her future projects are expected to delve deeper into understanding the biochemical mechanisms underlying cancer cell resistance and finding novel ways to target them using natural compounds and engineered nanoparticles.

In summary, Dr. Fatemeh Moradian is a biochemist whose career is marked by innovative research, impactful teaching, and a commitment to scientific discovery. Her work continues to inspire and influence both her peers and the next generation of scientists.

🎓Publication 

In vitro study of the expression of autophagy genes ATG101, mTOR and AMPK in breast cancer with treatment of lactoferrin and in silico study of their communication networks and protein interact

  • Authors   :Atefeh Mashhadi Kholerdi; Fatemeh Moradian; Havva Mehralitabar
  • Journal    :Biophysics and Molecular Biology
  • Year         :2024

Identification, Isolation, Cloning, and Expression of a New Alkaline Serine Protease Gene from Native Iranian Bacillus sp. RAM 53 for Use in the Industry

  • Authors   : Aliakbar Alei; Fatemeh Moradian; Ayoub Farhadi; Mehdi Rostami
  • Journal    :Applied Biochemistry and Biotechnology
  • Year         :2023

Nanoencapsulation of oral‐pharmaceutical lactoferrin using chitosan and the evaluation of stability against trypsin and pepsin and its antibacterial effect

  • Authors   :Ijaz, R., Waqas, M., Mahal, A., … Alatawi, N.S., Aloui, Z.
  • Journal    :Journal of Molecular Graphics and Modelling,
  • Year         :2024

Rational designing of phenothiazine dioxide based hole transporting materials for efficient perovskite solar cells

  • Authors   : Farzaneh Hedyeloo; Fatemeh Moradian; Mehran Rostami
  • Journal    :Micro & Nano Letters
  • Year         :2023

The effect of lactoferrin on ULK1 and ATG13 genes expression in breast cancer cell line MCF7 and bioinformatics studies of protein interaction between lactoferrin and the autophagy initiation complex

  • Authors   : Zahra Karabi; Fatemeh Moradian; Mitra Kheirabadi
  • Journal    :Cell Biochemistry and Biophysics
  • Year         :2022